Health
Neumora Plunges After Major Depression Drug Fails in Study
Neumora is running two more final-stage trials of the drug, and is developing a number of other drugs for brain disorders.
Photographer: Alex Kraus/BloombergThis article is for subscribers only.
Neumora Therapeutics Inc.’s shares plummeted the most on record after the company’s experimental drug for the treatment of major depressive disorder failed to show a benefit in a final-stage study.
Patients who received Neumora’s navacaprant didn’t show a statistically significant improvement in a measurement of depression symptoms, the company said Thursday. The shares fell as much as 83% at the New York market open, the most since they began trading in September 2023.